Piper Sandler Maintains Overweight on Biogen, Raises Price Target to $360
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Biogen (NASDAQ:BIIB) and raises the price target from $346 to $360.
June 01, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Biogen and raises the price target from $346 to $360.
The news of Piper Sandler maintaining an Overweight rating on Biogen and raising the price target from $346 to $360 is positive for the company. This indicates that the analyst has a bullish outlook on the stock, which could lead to increased investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100